Glytec Receives Another Patent Allowance for Therapy Advisor®

The company notes currently under development, the new product will extend the company’s core competencies beyond insulin optimization to include oral, inhaled and non-insulin injectable diabetes medications.

Glytec Receives Five Additional Patent Allowances for its Diabetes Therapy Management Software

Poised to address diabetes on a global scale, the company expands its intellectual property protections in the United States and abroad.

Case Studies Presented: Highlight Millions in Hospital Cost Savings with Improved Glucose Control

A series of studies and presentations included in the 6th International Hospital Diabetes Meeting highlighted the high cost of poor glucose management, and in particular, severe hypoglycemia (<40 mg/dL) in the acute care setting. With thirty to...